Geron Corp stock is traded at $0.967, with a volume of 7,088,465. It is down -2.72% in the last 24 hours and down -19.42% over the past month. Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Previous Close:
$0.994
Open:
$0.988
24h Volume:
7,088,465
Relative Volume:
0.39
Market Cap:
$622.98M
Revenue:
$196.12M
Net Income/Loss:
-$69.59M
P/E Ratio:
-
EPS:
-$0.1043
Net Cash Flow:
-$126.13M
1W Performance:
-2.30%
1M Performance:
-19.42%
6M Performance:
-31.42%
1Y Performance:
-15.91%
1-Day Range:
$0.95$0.988
1-Week Range:
$0.9412$1.03
52-Week Range:
$0.84$2.01
Geron Corp Stock (GERN) Company Profile
Name
Geron CorpSector
HealthcareIndustry
BiotechnologyPhone
(650) 473-7700Address
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS